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Abstract The excessive release of inflammatory cytokines
occasionally induces life-threatening hemophagocytosis re-
ferred to as hemophagocytic syndrome (HPS). A similar con-
dition, histiocytic hyperplasia with hemophagocytosis
(HHH), is often seen in bone marrow collected during autop-
sy. Unlike HPS, the pathogenesis of HHH remains unclear.
Therefore, we performed a clinicopathological analysis of
HHH from 70 autopsy cases at the University of Fukui Hos-
pital. HHH was detected in 29 of 70 autopsies (41.4 %) and
was significantly complicated with hematological diseases
(p<0.05) and sepsis (p<0.05). The percentage of macro-
phages in bonemarrow (BM) nucleated cells was significantly
increased in HHH (p<0.001). Data from medical records
indicated no significant changes, except for the minimum
values of white blood cell counts (p<0.05) and platelet counts
(p<0.05) in HHH patients as compared with non-HHH pa-
tients. Concentrations of inflammatory mediators including
IL-1β, IL-6, and IL-8 were significantly increased in HHH
patients. Multivariate risk factor analysis identified hemato-
logical diseases (odds ratio (OR), 11.71), ≥15 % BM macro-
phages (OR, 9.42), sepsis (OR, 7.77), and high serum IL-6
levels (OR, 1.00) as independent risk factors for HHH. HHH
with hypocellular BM, the most aggressive form of HHH, was
recognized in 8 of 29 HHH patients and was associated with
≥25 % BM macrophages (p<0.001), leukocytopenia
(p<0.05), and high IL-8 levels (p<0.05). None of the HHH
patients fulfilled the diagnostic criteria of HPS. These findings
suggest that HHH is a different entity from HPS and that it
preferentially develops under conditions of excessive inflam-
mation and its associated risks, such as hematological diseases
and sepsis.
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Introduction
The systemic release of excessive amounts of inflammatory
cytokines results in severe clinical disorders such as acute
respiratory distress syndrome, disseminated intravascular co-
agulation (DIC), septic shock, and multi-organ failure [1].
Simultaneously, the mononuclear–macrophage system is of-
ten dramatically activated [2], so that some patients develop a
rare life-threatening syndrome called hemophagocytic syn-
drome (HPS) or hemophagocytic lymphohistiocytosis [3, 4].
The hallmark of HPS is sustained inflammatory cytokinemia
due to genetic inheritance, infections, malignant lymphoma,
and collagen diseases [3, 5, 6]. Patients with HPS develop
persistent high fever, pancytopenia, hepatosplenomegaly,
lymphadenopathy, and elevated levels of liver transaminases,
bilirubin, lactate dehydrogenase, ferritin, and triglycerides [4,
7]. Histopathological examination reveals the presence of
activated macrophages in hematopoietic organs such as bone
marrow, liver, spleen, and lymph nodes, where they often
engulf erythrocytes and hematopoietic nucleated cells [4].
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Bone marrow samples from deceased patients often reveal
similar findings of hemophagocytosis [2, 8]. This phenome-
non, known as histiocytic hyperplasia with hemophagocytosis
(HHH), can be observed in patients with sepsis, viral and non-
viral infections, and advanced malignancies [8, 9]. Based on
these observations, we hypothesized that the pathogenesis of
HHHmay be initiated by a series of cytokine storms including
the release of inflammatory interferon (IFN)-γ, tumor necrosis
factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, and IL-18
cytokines, and IL-8 chemokine, as occurs in HPS [5, 6, 10].
However, it remains controversial whether the development of
HHH is caused by malignant diseases [2], and the pathogen-
esis of HHH remains obscure. In the present study, we inves-
tigated the pathogenesis of HHH by performing a postmortem
analysis of 70 patients with HHH. The primary outcome was
to identify risk factors for the development of HHH, and the
secondary endpoint was to analyze the inflammatory cytokine
profiles that characterize HHH by using serum collected at
autopsy. We found that HHH preferentially developed under
conditions of excessive inflammation, including hematologi-
cal diseases such as leukemia, lymphoma, and aplastic anemia
and sepsis, and that its onset and severity were associated with
pro-inflammatory IL-6 and IL-8, respectively.
Materials and methods
Patients and criteria for HHH
During the 3-year study period, we performed 87 autopsies.
Seven of these cases were excluded due to the inability to
collect serum because of coagulation, and ten cases were
excluded because only a partial dissection was performed.
The remaining 70 patients (39 men and 31 women) ranged
in age from 0 to 94 years (median age, 68 years) at the time of
death. Autopsies were performed at the University of Fukui
Hospital and were retrospectively examined. Written in-
formed consent was obtained from the families of each de-
ceased patient prior to enrollment. All research protocols were
approved by the ethics review board at the University of Fukui
Hospital and conformed to the provisions of the Declaration of
Helsinki.
The activity of hemophagocytosis was categorized though
microscopic examination of bone marrow as follows: (a) mild
HHH, several high-power fields must be searched to find
hemophagocytosis; (b) moderate HHH, 1–3 hemophagocytic
cells per high-power field; (c) severe HHH, more than 3
hemophagocytic cells per high-power field; and (d) hypoplas-
tic HHH (hypo-HHH), severe HHH with hypocellular bone
marrow. We assumed that cases showing moderate HHH to
hypo-HHH represented HHH in accordance with previously
described criteria [2, 8].
Lists of inspection data
Data including age, sex, diagnosis on admission, complica-
tions, DIC, infectious disease, sepsis, duration until autopsy,
and cause of death were obtained from clinical and autopsy
records (Electronic supplementary material (ESM) Table 1).
Mean duration until autopsy was 2.9±2.6 h (1–15.5 h; median
duration, 2 h) after the patient’s death. This time was similar in
cases with HHH (3.4±3.3 h) and with non-HHH (2.7±2.0 h).
Table 1 Patient characteristics with or without HHH
Category Subcategory Total HHH No HHH P*
Number of patients 70 29 41
Age Average 66.5 65.4 66.9
Range 0-94 52-91 0-94
Median 68 65 71
Sex Male 39 16 23
Female 31 13 18
Hematological diseases 19 14 5 <0.05
Malignancy All 49 22 27
Hematological 18 13 5 <0.05
Solid 31 9 22
Infection All 42 22 20
Sepsis 18 13 5 <0.05
Pneumonia 16 12 14
DIC 32 18 14
Shock 17 9 8
HHH histiocytic hyperplasia with hemophagocytosis, DIC disseminated intravascular coagulation
*Adjusted using the Holm method for multiple testing
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Sepsis was verified by the repeated detection ofmicrobes from
ante-mortem blood cultures from patients who met the criteria
of systemic inflammatory response syndrome [11, 12] or by
the detection of scattered micro-abscesses with or without
bacterial, fungal, or viral inclusion bodies in histopathological
studies of different tissues. DIC was diagnosed based on the
criteria of the Japanese Ministry of Health, Labor and Welfare
[13] or from the existence of fibrin thrombi in tissue sections
collected during autopsy. Shock was pathologically confirmed
by detecting shock-related morphological changes including
diffuse alveolar damage (shock lung), scattered focal or sub-
massive necrosis around the central hepatic vein (shock liver),
and/or acute tubular necrosis (shock kidney) [1]. Hepatomeg-
aly was defined as a liver weight greater than 1,300 g (normal
range in Japanese people, 900–1,300 g), and splenomegaly
was defined as a spleen weight of 130 g or greater.
The maximum and minimum white blood cell (WBC)
counts, minimum hemoglobin (Hb) level and platelet count
(Plt), and peak serum values of aspartate aminotransferase
(AST), triglyceride, ferritin, and soluble IL-2 receptor (sIL-
2R) from within 100 days prior to death were collected from
medical records.
Morphological analysis and immunohistochemical staining
Thin sections of paraffin-embedded bone marrow were
stained with hematoxylin and eosin. Activated macrophages
were evaluated by immunohistochemical staining with prima-
ry anti-CD68 antibody (DAKO, Kyoto, Japan) and antibody
against galactin-3 (Nichirei, Tokyo, Japan), a carbohydrate-
binding lectin secreted by activated macrophages [14]. A
rabbit polyclonal anti-CD3 antibody (DAKO) was used to
determine the number of T lymphocytes. The Berlin blue stain
was performed to detect intra- and extracellular iron deposi-
tion [8]. The sections were evaluated by two different pathol-
ogists who specialize in the pathophysiological analysis of
infection and inflammatory diseases [15, 16].
Cytokine analysis
Blood samples were collected from the right atrium by inser-
tion of an 18-G needle attached to a 20-ml syringe after
resection of the ribs and cardiac sac at autopsy. After clotting,
the blood was spun at 1,000×g for 10 min at room tempera-
ture. The separated serum was transferred to 1.5-ml tubes and
stored at −80 °C until analysis. The levels of inflammatory
TNF-α, IL-1β, IL-6, IL-10, and IL-12 cytokines, and IL-8
chemokine were determined by flow cytometry (FACs
Calibur; Becton Dickinson, Franklin Lakes, NJ) performed
with a Human Inflammation Kit (BD Biosciences, San Diego,
CA) according to the manufacturer’s protocol. IFN-γ was
measured by using a BD cytometric bead array (Becton Dick-
inson) as described before [17]. If the measured levels
exceeded the upper limits of the equipment, serumwas diluted
with saline and then re-evaluated by the same method.
Statistical analysis
Statistical analysis was performed by using the χ2 test and
Mann–Whitney U test. Pearson and Spearman correlation
coefficients were calculated as appropriate. Significant asso-
ciations with HHH were further analyzed by using logistic
regression analysis. P values were adjusted by using the Holm
method for multiple testing [18], and the results before and
after the adjustment are shown in ESM Tables 2 and 3. Values
of p<0.05 were accepted as statistically significant. All statis-
tical analyses were performed with Ekuseru-Toukei 2010
software (Social Survey Research Information, Tokyo, Japan).
Results
Patient characteristics with HHH
Twenty-nine of 70 patients (41.4 %) were categorized as
having HHH. The HHH group consisted of high-grade cases
demonstrating moderate HHH (n=10), severe HHH (n=11),
or hypo-HHH (n=8). The remaining 41 patients categorized
as having no HHH consisted of 14 patients with mild HHH
and 27 normal cohorts. Bone marrow cellularity of the 70
patients was characterized as hypercellular (n=26), slightly
hypercellular (n=3), normocellular (n=28), slightly
hypocellular (n=1), and hypocellular (n=12). Representative
morphological features are shown in Fig. 1. CD68-expressing
cells were scattered throughout all bone marrow sections. In
particular, severe HHH and hypo-HHH cases contained large
amebic histiocytes expressing both CD68 and galectin-3 pro-
teins; these cells were considered to represent activated mac-
rophages. The cytoplasm of many activated cells contained
engulfed erythrocytes, nucleated cells, and/or vacuoles. The
percentage of CD68-positive cells in the bone marrow nucle-
ated cell number was significantly increased in patients with
HHH than in patients without HHH (25.2 %±20.0 % vs.
12.1 %±4.0 %, p<0.001) (Fig. 2). Clinical characteristics of
patients with or without HHH are shown in Table 1. Hema-
tological diseases (p<0.05), hematological malignancies
(p<0.05), and sepsis (p<0.05) were significantly more com-
mon in patients with HHH than in patients without HHH.
Malignancies, pneumonia, and shock were not associated
with HHH.
Sepsis as a critical cause of death in HHH
To clarify the characteristic causes of death in HHH, the
causes of death were categorized (Table 2). The following
causes of death were identified in the 29 HHH patients: acute
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respiratory distress syndrome (ARDS)/sepsis/septic shock
(n=11), cancer (n=6), organ failure such as congestive heart
failure or liver failure (n=6), pneumonia (n=3), and shock
other than septic shock (n=3). Organ failure was the predom-
inant cause of death in non-HHH patients, followed by shock
and cancer. Death caused by sepsis/septic shock or ARDS
occurred in only two non-HHH cases. The percentage was
significantly lower than that of HHH cases (2/41 vs. 11/29,
p<0.05).
The pathogens isolated by microscopic inspection from
septic HHH patients were fungi (n=6; Candida in three pa-
tients, Aspergillus in two patients, and Fusarium in one
patient), cocci (n=6), bacilli (n=3), and cytomegaloviruses
(CMV) (n=3). Three different pathogens (fungus, CMV, and
cocci) were isolated from two patients, and a female patient
with microscopic polyangiitis had both Candida and
Aspergillus infections. In contrast to HHH patients, three
patients with cocci and one patient with bacilli were found
among the 41 non-HHH patients.
High serum inflammatory cytokine levels in HHH
HPS is induced by the simultaneous release of cytokines such
as IFN-γ, TNF-α, IL-6, IL-1β, IL-10, IL-12, IL-8, and
Fig. 1 Morphological features of bone marrow at autopsy in patients
with HHH. (Top line) Low-power magnification of bone marrow stained
by hematoxylin and eosin. (2nd line) High-power magnification of HE-
stained bone marrow. Activated macrophages engulfing erythrocytes and
nucleated cells were scattered in severe HHH (center column) and hypo-
HHH (right column) sections. (3rd line) Immunohistochemical staining
with anti-CD68 antibody. Although CD68-positive macrophages,
including brown deposits in the cytoplasm, were present in all bone
marrow tissues, large amoebic-shaped cells were only noted in severe
HHH and hypo-HHH bone marrow. (Bottom line) Immunohistochemical
staining of galectin-3 secreted by active macrophages. Galectin-3 was
expressed in bone marrow from severe HHH and hypo-HHH patients.
HHH, histiocytic hyperplasia of hemophagocytosis; HE, hematoxylin
and eosin; LPF, low-power field; HPF, high-power field
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macrophage-colony stimulating factor [19]. In this study, IL-6
(20,662.2±28,447.0 pg/ml vs. 4,262.5±11,769.6 pg/ml,
p<0.001), IL-1β (749.8±2,383.8 pg/ml vs. 95.5±561.1 pg/
ml, p<0.05), and IL-8 (24,439.7±42,733.5 pg/ml vs. 577.0±
816.1 pg/ml, p<10−6) levels were significantly increased in
HHH patients as compared with patients without HHH, while
IL-12, IFN-γ, TNF-α, and IL-10 concentrations showed no
statistically significant differences between the HHH and non-
HHH groups (Fig. 3a, Table 3, and ESM Table 2).
Correlations among serum cytokine levels were also ana-
lyzed (Fig. 3b). In HHH patients, TNF-α was significantly
correlated with IL-10 (r2=0.819, p<10−10), IL-1β (r2=0.679,
p<10−7), and IL-8 (r2=0.530, p<10−5). Correlations were
also detected between IL-10 and IL-1β (r2=0.599, p<10−6),
IL-10 and IL-8 (r2=0.576, p<10−5), and IL-1β and IL-8 (r2=
0.630, p<10−6).
Multivariate risk factor analysis for HHH
To elicit the critical risk factors for HHH, logistic regression
analysis was performed with variables that were significant in
the univariate analysis. The presence of hematological dis-
eases was associated with the development of HHH (odds
ratio=11.71; 95 % confidence interval (CI), 1.83–73.93,
p<0.01) (Table 4). Other factors associated with increased
risk include 15% ormore of bonemarrowmacrophages (odds
ratio=9.42; 95 % CI, 2.14–41.58, p<0.01), sepsis (odds ra-
tio=7.77; 95 % CI, 1.48–40.9, p<0.05), and high serum IL-6
levels (odds ratio=1.00; 95 % CI, 1.00–1.0001, p<0.05).
Pathophysiological features of hypo-HHH
Most HPS patients have pancytopenia, which makes them
susceptible to becoming immunocompromised. However,
hypocellular bone marrow is rare in HPS patients, and there
have been no previous reports of HHH with marrow hypopla-
sia. In the present study, we found eight HHH patients with
both pancytopenia and hypocellular bone marrow. We there-
fore investigated the characteristics of patients with hypo-
HHH (Table 5 and ESM Table 3). The absolute number of
CD68-positive macrophages in the bone marrow was in the
same range in each category (Fig. 4a). The percentage of
macrophages in the bone marrow was significantly increased
in hypo-HHH as compared with other types of HHH and non-
HHH (Fig. 4b). Interestingly, the rate was similar between
severe-HHH and moderate-HHH, and between mild-HHH
and no-HHH. Thus, we compared the characteristics of
hypo-HHH, other-HHH (including severe- and moderate-
HHH), and no HHHwith both mild-HHH and normal cohorts.
As shown in Fig. 4c, seven of eight hypo-HHH patients had
more than 25 % macrophages in the bone marrow. The hypo-
HHH group had dramatically decreased minimum WBC
counts (0.6±0.7×103/μl). Additionally, the IL-8 concentration
was significantly increased in hypo-HHH patients as compared
with other HHH patients (57,155.8±62,993.6 pg/ml vs.
11,976.4±24,010.6 pg/ml, p<0.01, Fig. 4c). Six of the eight
hypo-HHH patients received chemo-radiotherapies consisting
of allogeneic peripheral blood stem cell transplantation (n=2),
chemotherapy (n=3), and splenic irradiation (n=1) (Table 6).
The mean duration from the end of the final therapy to death
Fig. 2 Percentage of macrophages in the bone marrow nucleated cells.
The macrophages in the bone marrow were evaluated by CD68 immu-
nohistochemical stain. Bone marrow nucleated cells were counted as
Giemsa-staining positive cells. HHH, histiocytic hyperplasia of
hemophagocytosis
Table 2 Cause of the patient’s death with or without HHH
HHH No HHH
ARDS/sepsis/septic shock 11 2
Pneumonia/other infection 3 4
Other shock/bleeding 3 11
Cancer death/cachexia/emaciation 6 10
Organ failure/heart, respiratory, liver, or renal 6 13
HHH histiocytic hyperplasia with hemophagocytosis, ARDS acute respi-
ratory distress syndrome
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was 79.8±94.7 days (range, 20–270 days). Two of the eight
hypo-HHH patients had not received myeloablative therapies,
suggesting that the influence of chemo-radiotherapies was
limited to the initiation of hypo-HHH.
Regarding CD3 immunostaining and iron staining of bone
marrow samples, the Fe staining detected hemophagocytic
histiocytes. However, no significant association was obtained
between the number of CD3-positive T lymphocytes and the
severity of HHH or between the Fe-positive macrophage
counts and the degree of HHH (ESM Figures 1 and 2).
Discussion
HPS, which is characterized by the proliferation of activated
macrophages with hemophagocytosis, is a rare syndrome [4,
6, 7, 20]. In contrast, HHH was detected in 41.4 % of this
study cohort. Studies performed at two different university
hospitals identified HHH in 35 of 107 deceased patients
(32.7 %) [8] and 102 of 230 autopsies (44.3 %) [2]. In
addition, the patients with mild HHH form the largest cohort
in these previous studies. These data are consistent with our
results, and together, they suggest that HHH is a common
phenomenon in patients who die in major hospitals.
Two major categories of risk factors for HHH have been
identified: (i) intrinsic factors, such as advancedmalignancies,
sepsis, and multi-organ failure; and (ii) extrinsic factors, such
as blood transfusions and treatment intensity [2, 8, 21]. How-
ever, some controversial results have been obtained. In com-
parison with non-HHH patients, HHH patients had a signifi-
cantly increased frequency of hematological diseases, hema-
tological malignancies, and sepsis. Independent risk factors
Fig. 3 Serum cytokine analyses
in patients with HHH. a Serum
cytokine levels in patients with
HHH. Serum was collected from
the right atrium of each deceased
patient and stored at −80 °C until
analysis. The cytokine levels were
measured by flow cytometry.
Grey bars represent data derived
from HHH patients, and open
bars represent data from non-
HHH patients. The data are
shown by a box and whisker plot.
X’s indicate statistical outliers. b
Correlation coefficients among
inflammatory cytokines and
chemokines in HHH patients.
Data represent the square of the
correlation coefficient value. *,
**, ***, ****, and ***** indicate
statistically significant differences
with p values <0.01, <10−5,
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for HHH identified by logistic regression analysis were he-
matological diseases, ≥15 % bone marrow macrophages, sep-
sis, and high IL-6 levels. Hematological diseases were the
most striking risk factor, and they have been implicated in
severe immunodeficiency. Nevertheless, an underlying immu-
nodeficient state at the onset of HHH and HPS seems under-
represented, unlike the documented infections for the most
common setting of secondary HPS [22]. However, HHH
developed preferentially in our hematological subjects with
significantly decreased nadir WBC counts, particularly in
hematological patients with hypo-HHH. Hematological pa-
tients with leukemia, malignant lymphoma, myelodysplastic
syndrome, or aplastic anemia are potentially immunosup-
pressed, which would make them susceptible to severe infec-
tions such as pneumonia, febrile neutropenia, and bloodstream
infections [15, 23]. Hematological disorder itself is not a
condition of excessive inflammation; however, its associated
risk of infections may lead to inflammation. The importance
of severe infection for HHH may be validated by the other
independent risk factors of sepsis and high IL-6 levels. In fact,
sepsis is defined as the systemic response to infection and is
involved in the systemic inflammatory response syndrome
[11, 12]. IL-6 concentrations are proportional to the severity
of infection [24]. The kinetics of inflammatory mediators after
death remains unclear. Indeed, few studies have provided
sequential analyses of inflammatory cytokine levels after
death. As for the IL-6 and IL-1β concentrations, the mean
levels tend to gradually increase at 24 h after death in both
septic patients and normal cohorts, but several cases have
shown decreased levels after death [25, 26]. Because our
autopsies were performed within 24 h of death (3.0±2.6 h;
range, 1–15.5 h), postmortemmodifications are assumed to be
slight. The results of previous studies together with the present
results suggest that underlying diseases characterized by ex-
cessive inflammatory conditions are the most striking initia-
tors of HHH.
The median t ime from onset to diagnosis of
hemophagocytic lymphohistiocytosis is 3.5 months [19], and
Table 3 Clinical and physiological findings of patients with or without
HHH
HHH (n=29) No HHH (n=41) Pa
value
Organomegaly
Hepatomegaly 16 (55.2 %) 15 (36.6 %)
Splenomegaly 16 (55.2 %) 12 (29.3 %)
Laboratory data
WBC max (x103/μl) 18.5±13.6 17.4±8.9
WBC min (x103/μl) 4.3±7.4 5.7±3.3 <0.05
Hb (g/dl) 7.2±2.4 8.1±2.5
Plt (x104/μl) 5.7±10.8 11.6±9.7 <0.05
AST (IU/l) 147±170 766±2,807
Triglyceride (mg/dl) 239±244 147±89
IL-12 (pg/ml) 19.0±92.2 13.4±64.4
IFN-γ (pg/ml) 361.2±1,854.2 17.3±50.0
TNF-α (pg/ml) 8.4±26.7 1.4±1.2













HHH histiocytic hyperplasia with hemophagocytosis, WBC max maxi-
mum number of WBC, WBC min minimum number of WBC
aAdjusted using the Holm method for multiple testing
Table 4 Multivariate risk analysis for HHH
Odds ratio 95 % CI P value
Hematological diseases 11.71 1.83–74.93 <0.01
Sepsis 7.77 1.48–40.9 <0.05
WBC (min) 1.12 0.94–1.33 0.20
IL-6 1.00 1.00–1.0001 <0.05
BM macrophages (≥15 % ) 9.42 2.14–41.58 <0.01
HHH histiocytic hyperplasia with hemophagocytosis, WBC (min) mini-
mum number of WBC, BM bone marrow, CI confidence interval







Hematological diseases 7 (87.5 %) 7 (33.3 %)
BM macrophages
(≥25 %)
7 (87.5 %) 1 (4.8 %) <0.001
WBC max (×103/μl) 17.9±16.6 18.7±12.8
WBC min (×103/μl) 0.6±0.7 5.8±8.2 <0.05
Hb (g/dl) 6.1±1.2 7.6±2.6
Plt (×104/μl) 1.1±1.1 7.5±12.4
Triglyceride (mg/dl) 408±315 155±150
IL-12 (pg/ml) 1.8±1.4 25.6±108.3
IFN-γ (pg/ml) 33.4±65.8 486.0±2,780.0
TNF-α (pg/ml) 20.6±3.8 49.5±7.6











HHH histiocytic hyperplasia with hemophagocytosis, WBC max maxi-
mum number of WBC, WBC min minimum number of WBC
aAdjusted using the Holm method for multiple testing
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the activated inflammatory cytokines often persist for 100 days
[5]. In addition, the impairment of the Th1 and Th2 balance
promotes secretion of Th1 cytokines such as IFN-γ, IL-4, IL-
12, and IL-18, followed by the elevation of pro-inflammatory
TNF-α, IL-1β, and IL-6 cytokines, IL-8 chemokine, and anti-
inflammatory IL-10 cytokine [5, 10, 19]. However, the pro-
files of inflammatory cytokines have not been previously
analyzed in HHH patients. We found that HHH patients had
significantly higher levels of IL-1β, IL-6, and IL-8 as com-
pared with patients without HHH. Several mediators includ-
ing TNF-α, IL-1β, IL-8, and IL-10 showed strong positive
correlations, indicating that the secreted cytokines were close-
ly associated. The released cytokines were similar to the
cytokine profiles described for septic shock, severe febrile
neutropenia, and in vitro sepsis model experiments that used
peripheral blood monocytes [27–29]. Moreover, significant
correlations are noted among inflammatory cytokines in se-
vere inflammatory diseases [28, 29]. These findings suggest
that a series of inflammatory cytokine releases was a feature of
HHH as well as other severe inflammatory diseases and that
monocytes and macrophages were responsible for the produc-
tion of these cytokines. On the other hand, the levels of IFN-γ
did not show a statistically significant difference between the
HHH and non-HHH patients. The levels of IFN-γ decrease
rapidly with improvements in the HPS syndrome [5, 19],
suggesting that the IFN-γ concentration had already attenuat-
ed at the time of death.
HHH patients have been reported to have normocellular
bone marrow, but we identified eight HHH patients with
hypocellular bone marrow. Hypo-HHH was characterized by
an increased rate of migrated macrophages in the bone mar-
row, severe leukocytopenia, and high serum IL-8 levels; how-
ever, there was no increase in the absolute number of macro-
phages, indicating that the functional activation of macro-
phages resulted in the engulfment of bone marrow hemato-
poietic cells. High IL-8 concentrations may be associated with
the seriousness of HHH. Indeed, the chemokine concentration
was significantly increased according to the severity of HHH.
Fig. 4 Features of hypo-HHH. a
Absolute number of CD68-
positive macrophages in the bone
marrow in different types of
HHH. b Percentage of
macrophages in the bone marrow
nucleated cells in each category.
Grey bars represent data derived
from HHH patients, and open
bars represent data from non-
HHH patients. The data are
shown by a box and whisker plot.
X’s indicate statistical outliers. c
Characteristics of hypo-HHH in
comparison with other-HHH and
non-HHH patients. Closed bars
represent data from hypo-HHH
patients, oblique bars represent
data from HHH patients, and
open bars represent data from
non-HHH patients. Data are
presented as the mean ± standard
deviation. WBC min, minimum
number of white blood cells;
HHH, histiocytic hyperplasia of
hemophagocytosis; hypo-HHH,
hypoplastic HHH
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Even in the patients with mild HHH, the IL-8 concentration
was greater than that in the normal cohort (714.2±649.0 pg/ml
vs. 505.8±893.7 pg/ml, p<0.05), although their macrophage
counts were in the same range. Conversely, the minimum
WBC count of mild HHH was significantly lower than that
of non-HHH (4.2±2.9×103/μl vs. 6.5±3.2×103/μl, p<0.05).
IL-8 is a CXC chemokine produced by monocytes and mac-
rophages that attracts neutrophils to inflamed sites for phago-
cytosis and killing of pathogens [27, 30]. The IL-8 concentra-
tions are inversely correlated with leukocytopenia, and the
peak value is seen during the neutropenic phase of hemato-
poietic stem cell transplantation [31]. These findings suggest
that the high IL-8 level in hypo-HHH is the consequence of
severe leukocytopenia due to excessive activation of bone
marrow macrophages.
Strauss et al. described HPS as the most severe variant of
HHH [8]. However, none of the HHH patients in their study or
in our study fulfills the diagnostic criteria for HPS. Indeed, HPS
and HHH have hypercytokinemia in common, but HPS is a
syndrome with defined clinical and laboratory features, one of
which is the occurrence of increased histiocytes with
hemophagocytosis. By contrast to HPS, the development of
HHH is most often a multifactorial process rather than one
related to a single underlying condition [2]. Therefore, HHH
should be considered as a different disease entity from HPS.
Additionally, we found a new feature of HHH in that the
absolute number of BM histiocytes was in a similar range in
the presence or absence of HHH, indicating that the essential
feature of HHH is the augmentation of hemophagocytic histio-
cytes rather than histiocytic hyperplasia. Hence, we propose a
tentative definition of this disorder as “polyhemophagocytosis
(PHP)” to avoid confusion with HPS (Table 7) [2, 8].
In conclusion, we found that conditions of excessive in-
flammation, such as hematological disorders and sepsis, ap-
pear to be the strongest initiators of HHH development. In
addition, the development of HHH was also associated with
increased IL-6 and IL-8 concentrations. Although further
investigations of HHH are needed, insights into HHH can be
gained from the analysis of data from the present study.
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